NCT02345421

Brief Summary

The objective of this study is to determine the frequency of Lysosomal Acid Lipase Deficiency (LAL D) by lysosomal acid lipase (LAL) enzyme activity assay in patients who are considered to be at risk.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
640

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2014

Shorter than P25 for all trials

Geographic Reach
1 country

15 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2014

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

January 19, 2015

Completed
7 days until next milestone

First Posted

Study publicly available on registry

January 26, 2015

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2015

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2015

Completed
Last Updated

May 24, 2016

Status Verified

May 1, 2016

Enrollment Period

9 months

First QC Date

January 19, 2015

Last Update Submit

May 23, 2016

Conditions

Keywords

LAL DCESDNASHNAFLDWilson'sNiemann PickFamilial Hypercholesterolemia

Outcome Measures

Primary Outcomes (1)

  • LAL D frequency based on LAL enzyme assay.

    The endpoint of this study is the frequency of LAL D in at-risk patients, based on results from the LAL enzyme assay.

    approximately 1 month

Study Arms (1)

At risk population

Eligibility Criteria

Age2 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients \>2 years of age who are at risk for a diagnosis of LAL D

You may qualify if:

  • Non-obese\*\* patients with elevated low-density lipoprotein (LDL)
  • Non-obese\*\* patients with low high-density lipoprotein (HDL)
  • Non-obese\*\* patients with unexplained and persistently elevated liver transaminases,
  • Non-obese\*\* patients with hepatomegaly
  • Patients with cryptogenic cirrhosis
  • Patients with biopsy-proven microvesicular or mixed micro/macrovesicular steatosis without a known etiology
  • Patients with presumed Familial Hypercholesterolemia (FH) in which genetic analysis was performed for the genes encoding the low-density lipoprotein receptor (LDLR), Apo-B and PCSK9 genes and no disease-causing mutations were identified
  • Patients with presumed FH with unclear family history
  • Patients with autosomal recessive hypercholesterolemia (other than homozygous FH)
  • Patients with autosomal recessive low HDL of unknown etiology
  • Also, patient must meet the following:
  • Patient or patient's parent or legal guardian (if applicable) consents to participate in the study and provides informed consent prior to any study procedures being performed. If the patient is of minor age; he/she is willing to provide assent where required per local regulations, and if deemed able to do so.
  • Patient is willing and able to comply with protocol requirements.
  • Patients who do not fall into one of the aforementioned categories (cohorts) but are considered highly suspicious for LAL D should be tested to rule out the disorder outside of the study at the discretion of the Investigator.

You may not qualify if:

  • Active viral hepatitis;
  • Other confirmed genetic liver diseases (e.g., Wilson's disease, hemochromatosis, alpha 1-antitrypsin).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (15)

Unknown Facility

Birmingham, Alabama, United States

Location

Unknown Facility

Phoenix, Arizona, United States

Location

Unknown Facility

Los Angeles, California, United States

Location

Unknown Facility

San Francisco, California, United States

Location

Unknown Facility

Gainesville, Florida, United States

Location

Unknown Facility

Jacksonville, Florida, United States

Location

Unknown Facility

Miami, Florida, United States

Location

Unknown Facility

New Orleans, Louisiana, United States

Location

Unknown Facility

Minneapolis, Minnesota, United States

Location

Unknown Facility

The Bronx, New York, United States

Location

Unknown Facility

Durham, North Carolina, United States

Location

Unknown Facility

Oklahoma City, Oklahoma, United States

Location

Unknown Facility

Portland, Oregon, United States

Location

Unknown Facility

Houston, Texas, United States

Location

Unknown Facility

San Antonio, Texas, United States

Location

MeSH Terms

Conditions

Wolman DiseaseNon-alcoholic Fatty Liver DiseaseHyperlipoproteinemia Type II

Condition Hierarchy (Ancestors)

Cholesterol Ester Storage DiseaseLipidosesLipid Metabolism, Inborn ErrorsMetabolism, Inborn ErrorsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesLysosomal Storage DiseasesInfant, Newborn, DiseasesLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesFatty LiverLiver DiseasesDigestive System DiseasesHyperlipoproteinemiasHyperlipidemiasDyslipidemias

Study Design

Study Type
observational
Observational Model
CASE ONLY
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 19, 2015

First Posted

January 26, 2015

Study Start

December 1, 2014

Primary Completion

September 1, 2015

Study Completion

October 1, 2015

Last Updated

May 24, 2016

Record last verified: 2016-05

Locations